Revolution Medicines (RVMD) Enterprise Value (2018 - 2026)

Revolution Medicines' Enterprise Value history runs 9 years deep, the most recent figure standing at -$1.9 billion for Q1 2026.

• In Q1 2026, Enterprise Value rose 9.25% year-over-year to -$1.9 billion; the TTM figure through Mar 2026 stood at -$1.9 billion (up 9.25% YoY), while the FY2025 annual figure was -$2.0 billion, up 11.52% from the prior year.
• Enterprise Value was -$1.9 billion for Q1 2026 at Revolution Medicines, up from -$2.0 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$461.4 million in Q2 2022 to a low of -$2.3 billion in Q4 2024.
• Historically, Enterprise Value has averaged -$1.4 billion across 5 years, with a median of -$1.6 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value rose 28.61% in 2022, then sank 187.31% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$644.9 million in 2022, then tumbled by 187.31% to -$1.9 billion in 2023, then dropped by 23.55% to -$2.3 billion in 2024, then grew by 11.52% to -$2.0 billion in 2025, then advanced by 5.81% to -$1.9 billion in 2026.
• The last three Enterprise Value figures came in at -$1.9 billion (Q1 2026), -$2.0 billion (Q4 2025), and -$1.9 billion (Q3 2025), per Business Quant data.